a phase II study of chemoradiotherapy with CDDP+5-FU+DOC for postoperaitve loco-regional recurrent esophageal cancer

a phase II study of chemoradiotherapy with CDDP+5-FU+DOC for postoperaitve loco-regional recurrent esophageal cancer - a phase II study of chemoradiotherapy with CDDP+5-FU+DOC for postoperaitve loco-regional recurrent esophageal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019269

Enrollment

Registered

2015-10-07

Start date

2015-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative loco-regional recurrent esophageal cancer

Interventions

radiotherapy: 60Gy/30fx/6weeks (local field) CDDP: 40mg/m2 day1, 15, 29 DOC: 35mg/m2 day1, 15, 29 5-FU: 1000mg/m2 day1-5, 15-19, 29-33

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) performed esophagectomy and D2/3 dissection (R0 resectio) 2) loco-regional recurrence with CT and/or PET-CT 3) ECOG PS=0-2 4) age; 20-75 5) no severe complication 6) written informed consent

Exclusion criteria

Exclusion criteria: 1) with distant organ metastasis 2) with irradaiation history 3) recurrence after EMR 4) second primary 5) double active cancer 6) with severe complication 7) pregant female 8) active infection 9) regular use steroid 10) with pace maker or implantable cardioverter defibrillator

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
progression-free survival, toxicity	—

Countries

Japan

Contacts

Public ContactKeiichi Jingu

Tohoku university graduate school of Medicine Department of Radiuation Oncology

kjingu-jr@rad.med.tohoku.ac.jp+81-22-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026